The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the ...

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

This kind of drug is taken with an aromatase inhibitor, a type of anti-cancer ... for the same patient group in England via the Cancer Drugs Fund after NICE recommended interim funding in November ...

But getting PI3K drugs to work with tolerable side effects ... following progression on or after an aromatase inhibitor, with or without a CDK4/6 inhibitor, versus fulvestrant alone.

Novel selective FEN1 nuclease inhibitor shows synergy with PARP-targeting drugs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular ...